PCG
ESPR

Private Capital Group’s Esperion Therapeutics ESPR Stock Holding History

Private Capital Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Sell
216
-69
-24% -$391 ﹤0.01% 1696
2022
Q1 		$1K Buy
+285
New +$1.22K ﹤0.01% 1925

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Private Capital Group's ESPR Position: Q2 2022 in Review

Private Capital Group reduced its Esperion Therapeutics (ESPR) stake by 24% in Q2 2022, selling an estimated $391 and leaving 216 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

Private Capital Group first reported a position in ESPR in Q1 2022 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

  • Private Capital Group held 216 shares of Esperion Therapeutics worth $1K as of Q2 2022.
  • Private Capital Group sold 69 Esperion Therapeutics shares in Q2 2022, an estimated $391.
  • Esperion Therapeutics made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1696 holding.
  • Private Capital Group first reported a position in Esperion Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.